Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • đŸ”„
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Economy

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress

Last updated: June 24, 2025 1:16 am
Share
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
SHARE

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has recently made headlines as one of the top genomics stocks to buy according to hedge funds. The company presented promising three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) at the EAACI Congress 2025, showcasing positive results in patients with hereditary angioedema (HAE).

The data revealed that all 10 patients who received a single dose of lonvo-z remained attack-free for a median of 23 months, with a remarkable 98% mean reduction in monthly HAE attacks. Additionally, positive safety outcomes were observed across all treatment dosages. The Phase 3 HAELO trial, which has seen a majority of U.S. enrollment, has successfully completed screening ahead of schedule. Intellia Therapeutics, Inc. plans to launch lonvo-z in 2027 following the submission of a Biologics License Application (BLA) in 2026.

Lonvo-z, also known as NTLA-2002, is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The therapy has been designated as an Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, as well as a PRIority MEdicines (PRIME) by the EMA, highlighting its potential for treating rare diseases.

Administered intravenously at doses ranging from 25 to 75 mg, lonvo-z demonstrated dose-dependent reductions in kallikrein protein levels and sustained efficacy over the long term, with no significant treatment-related adverse effects reported.

While Intellia Therapeutics, Inc. (NASDAQ:NTLA) shows promise as an investment opportunity, some AI stocks may offer greater potential for returns with lower risk. For those interested in exploring undervalued AI stocks with significant upside potential, particularly in the context of current economic trends, a free report on the best short-term AI stock is available.

See also  Xi Jinping urges Vietnam to oppose Donald Trump’s tariff ‘bullying’

In conclusion, Intellia Therapeutics, Inc. continues to make strides in the field of genomics with their innovative gene editing therapies. The positive results from the lonvo-z trial offer hope for patients with HAE and underscore the company’s commitment to advancing precision medicine.

TAGGED:3yearCongressDataEAACIHAEIntelliaLonvozPositiveReportsTrial
Share This Article
Twitter Email Copy Link Print
Previous Article New Mexico Footprints Rewrite Timeline of Humans in America : ScienceAlert New Mexico Footprints Rewrite Timeline of Humans in America : ScienceAlert
Next Article Scarlett Johansson and Colin Jost’s Relationship Timeline Scarlett Johansson and Colin Jost’s Relationship Timeline
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Enforcing the Death Penalty Laws in the District of Columbia to Deter and Punish the Most Heinous Crimes

MEMORANDUM FOR THE ATTORNEY GENERAL                THE UNITED STATES ATTORNEY FOR THE DISTRICT                  …

September 25, 2025

nLIGHT, Inc. (LASR): A Bull Case Theory

Recently, we discovered a bullish thesis concerning nLIGHT, Inc. (LASR) shared on X.com by pennycheck.…

September 30, 2025

UEFA Champions League Matchday 7 schedule, live stream, storylines: Where to watch UCL on Paramount+

Atletico Madrid, on the other hand, have had a bit of a rollercoaster season so…

January 19, 2025

Brewer’s Yeast: A Protein Superfood for Longer Hair

Protein can come in unexpected forms, and one such surprising source is brewer’s yeast. This…

April 16, 2025

Bryan Greenberg and MichĂšle Laroque Join Cast

Exciting New Additions to the Cast of "Emily in Paris" Season 5 With filming of…

July 2, 2025

You Might Also Like

Verizon Communications Stock: Analyst Estimates & Ratings
Economy

Verizon Communications Stock: Analyst Estimates & Ratings

October 31, 2025
BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”
Economy

BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”

October 31, 2025
3 Must-Buy Stocks Fueling the Data Center Surge
Economy

3 Must-Buy Stocks Fueling the Data Center Surge

October 31, 2025
Shake Shack returns to profit in Q3 2025
Economy

Shake Shack returns to profit in Q3 2025

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?